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Multivariate data analysisThe HIV-1 Tat protein is released by infected cells and has numerous biological activities which might con-
tribute either to the impairment of the immune response or to viral dissemination and pathogenesis. To
date, the effects of Tat protein on metabolites remain unclear. In this study, a metabolomic study on serum
of HIV-1 Tat-induced ICR mice was performed to research the pathologic mechanism of Tat protein by
using gas chromatography coupled to mass spectrometry (GC/MS). Clear separations among the HIV-1 Tat-
induced mice and the inaTat-induced or control mice were observed by principal component analysis and
partial least-squares discriminant analysis based on the GC/MS spectral data. Additionally, 16 signiﬁcantly
changed metabolites in HIV-1 Tat-induced mice were identiﬁed that are involved in multiple perturbed met-
abolic pathways, which contributed to the elucidation of the complex pathogenic mechanism of Tat protein
and may shed new lights on future improvement of HIV-1 therapy.
© 2011 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus type 1 (HIV-1) Tat is a multifunc-
tional protein that contributes to virus replication as well as several
pathological symptoms of HIV-1 infections. Tat is released by infected
cells (Chang et al., 1997; Ensoli et al., 1993) and has numerous biolog-
ical activities that might contribute either to the impairment of the
immune response (Cohen et al., 1999; Subramanyam et al., 1993;
Viscidi et al., 1989) or to viral dissemination (Huang et al., 1994;
Marchio et al., 2005; Smith et al., 2003) and pathogenesis (Barillari
and Ensoli, 2002; Ensoli et al., 1990; Sabatier et al., 1991). Tat can af-
fect the expression of many cellular genes, inducing disturbances of
signal transduction pathways (Mischiati et al., 1999), angiogenic pro-
grams in endothelial cells (Rusnati and Presta, 2002), neuronal apo-
ptosis (Li et al., 2005), and the modulation of the expression of
several molecules involved in the initiation of immune responses
(Campbell and Loret, 2009). Furthermore, several in vivo experiments
have demonstrated detrimental consequences of the presence of Tat
in an organism. Studies of transgenic mice expressing Tat suggested
that this viral protein may contribute to the growth of many types
of tumors that frequently develop in patients during the course of
AIDS (Corallini et al., 1993). It has also been shown that Tat stimulates
apoptosis in the rat central nervous system and causes neurologic dis-
orders (Gavriil et al., 2000). Furthermore, Tat appears to be immuno-
suppressive when injected into mice (Agwale et al., 2002; Cohen et), yfchai@smmu.edu.cn
rights reserved.al., 1999), and it has also been shown to enhance AZT toxicity in a
transgenic mouse model (Prakash et al., 1997). Taken altogether,
the pathogenesis of Tat is very complex and needs to be further inves-
tigated. Considering its multi-bioactivities, ability to induce a pattern
of cytokines and complex pathogenesis, Tat was thought to act as a
“viral toxin” (Gallo, 1999). To date, the effects of the Tat protein on
metabolites remain unclear.
Metabolomics (the systems biology of small molecules) is a new
approach for the untargeted identiﬁcation of potential biomarkers
(Want et al., 2007). Metabolites are obvious candidates for biomarker
screening because they represent the downstream effect of enzyme
catalysis and other biotransformations, and they are smaller in num-
ber than the proteome. Although metabolomics initially emerged
using NMR, mass spectrometry (MS) has evolved as a powerful tech-
nique for the comprehensive proﬁling of the metabolome in, for ex-
ample, serum, urine, and cells (Want et al., 2007). The power of MS
in metabolomics arises from its sensitivity, speed, and ability to inter-
face directly with chromatography. Gas chromatography coupled
with mass spectrometry (GC/MS) has proven to be a robust metabo-
lomic tool and widely applied in metabolite identiﬁcation and quan-
tiﬁcation (Jonsson et al., 2004, 2005) due to its excellent resolution
and sensitivity. Coupling bioinformatics and biostatistics with this
technology platform permits the identiﬁcation and quantiﬁcation of
low weight molecules to characterize a whole organism's response
to a given condition.
The application of metabolomics to a viral infection or pathogene-
sis of a viral bioactive protein is a largely unexplored area (Wikoff et
al., 2008). Here we present the ﬁrst GC/MS-based metabolomic
study of Tat-induced mice serum. HIV-1 Tat-induced mice were
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fatty acids, and other metabolites, such as lactate, glutamine, uric acid
andα-tocopherol, which were related tomultiple perturbedmetabol-
ic pathways and contributed to the elucidation of the complex patho-
genic mechanism of the HIV-1 Tat protein.
Results
Puriﬁcation and characterization of recombinant Tat protein
The DNA encoding for the HIV-1 HXB2 strain Tat protein was am-
pliﬁed by overlapping PCR and the protein was expressed and puri-
ﬁed. The puriﬁed Tat protein was relatively pure and free of the
bulk of the bacterial proteins as assessed by SDS-PAGE electrophore-
sis (Fig. 2A, lane 7). Tat is particularly vulnerable to oxidative stresses
that modify its structure, inducing protein multimerization and ag-
gregation that leads to the loss of biological activity. Therefore, the
puriﬁed Tat protein was immediately lyophilized, stored at −80 °C,
and then resuspended in degassed PBS just before use.
As shown in Fig. 2A (bottom panel), the recombinant Tat protein
was tested and was speciﬁcally recognized by an anti-Tat monoclonal
antibody by western blot analysis. This ﬁnding demonstrated that the
protein was successfully expressed and puriﬁed.
One serious limitation to recombinant protein expression in
Escherichia coli is the copuriﬁcation of lipopolysaccharides (LPS)
which is the constituent component of Gram negative bacterial cell
walls and could be toxic to the cells and tissues of mammalian origin
(Beutler and Rietschel, 2003). Therefore, it is essential to remove en-
dotoxin completely from Tat expressed from a bacterial source. In this
study, Triton X-100 at 2% concentration (Petsch and Anspach, 2000;Fig. 1. Schematic ﬂowchart of the metabolic proﬁling strategy used in this study. The recom
mice were treated with the bioactive Tat protein, inaTat or PBS. Serum samples were extracte
to extract meaningful information in the complex GC/MS spectral data. Compounds with sign
samples and the inaTat-induced or control samples were identiﬁed using GC/MS NIST libraSiddappa et al., 2006) was used to extensively wash the columns to
remove endotoxin, which resulted in a reduction of endotoxin levels
in the eluted Tat to the order of approximately 500 (reduction from
400 EU/μg to 0.8 EU/μg) and 8000 times (reduction from 400 EU/μg
to 0.05 EU/μg) after Ni–NTA and ion-exchange chromatographies, re-
spectively. The ﬁnal concentration of endotoxin in the eluted Tat was
approximately 0.05 EU/μg of protein which is within the acceptable
limit (Petsch and Anspach, 2000).Recombinant Tat protein is transactivation competent
Tat is believed to be secreted into extracellular spaces from
infected cells, cross cell and nuclear membranes of the neighboring
cells efﬁciently, and transactivate latent viral promoters, thus enhanc-
ing viral infectivity (Ensoli et al., 1993). We tested the ability of the
puriﬁed recombinant Tat protein to enter target cells and transacti-
vate reporter genes under the control of the viral promoter. 293T
cells were transiently transfected with pLTR-GFP and incubated for
24 h. Although the cells transfected with pLTR-GFP and in the absence
of Tat showed GFP expression because of the strong constitutive ac-
tivity of LTR promoter, GFP expression in 293T cells was signiﬁcantly
higher in the presence of Tat (the left panel in Fig. 2B) than that in the
presence of PBS (the right panel in Fig. 2B) and inaTat protein (the
middle panel in Fig. 2B) suggesting efﬁcient Tat-transactivation by
the recombinant Tat protein. In addition, SEAP expression (Fig. 2C)
in 293T cells was determined with relative ratio of Tat group (15:1),
inaTat (1.8:1), PBS group (1.4:1) to control group (only transfected
with the pLTR-GFP), demonstrating that the puriﬁed Tat protein is
bioactive.binant Tat protein was expressed and puriﬁed, and its bioactivity was evaluated. ICR
d, derivatized and subsequently analyzed by GC/MS. Multivariate statistics was applied
iﬁcant contribution to the variation of metabolic proﬁles among the HIV-1 Tat-induced
ry and further veriﬁed by reference compounds available.
Fig. 2. (A) SDS-PAGE and western blot analyses of the puriﬁed Tat protein. The Tat protein was expressed and puriﬁed by Ni–NTA afﬁnity chromatography and further puriﬁed by SP
Sepharose fast ﬂow ion-exchange chromatography. A measured quantity of the protein was resolved on a 15% SDS-PAGE gel with protein molecular weight standards (M; Sigma, St.
Louis, Mo). Bottom panel shows the western blot analysis of the Tat protein resolved on a duplicate SDS-PAGE and electrophoretically transferred to a PVDF membrane. An anti-Tat
monoclonal antibody was used for the western blot analysis. (B) The recombinant Tat protein is transactivation competent. 293T cells were transiently transfected with pLTR-GFP
using a commercial lipid formulation. Twenty-four hours after the transfection, the cells were incubated with bioactive Tat protein, inaTat or PBS. Twenty-four hours following the
protein transfection, expression of GFP was measured using UV-ﬂuorescence microscopy. The top group was ﬂuorescent view and the bottom group was ﬂuorescent view with
corresponding light view. (C) Expression of alkaline phosphatase secreted into the medium was estimated at 24 h using lumino-meter. B, chemiluminescence values measured
using lumino-meter; B0, background SEAP expressed by 293T without Tat.
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The stability of the analytical method is very important to obtain
valid metabolomic data. In this study, the system stability was
expressed as the relative standard deviation (RSD) of the relative
peak areas of eight common ions (see section “System stability”).
The result was 6.17%–12.56%, demonstrating the robustness of the
method. This ﬁnding means that differences amid the test samples
from different individuals were more likely to reﬂect varied metabo-
lite proﬁles rather than analytical variation.
The typical total ion current chromatograms (TICs) of mouse sera
are shown in Fig. 3. By untargeted ﬁltration of ion peaks, the data
were simpliﬁed and 214 ion peaks were obtained. Application of
PCA to the data differentiated the control, inaTat and Tat-induced
groups (R2=0.52). As shown in Fig. 4A, all the samples of Tat group
are distributed in the left side of the ﬁgure and are well separated
from those of control and inaTat groups. Conversely, all of the sam-
ples from control and inaTat groups are distributed in the right side
of the ﬁgure and the inaTat group was close to the control group. It
suggested that inaTat protein caused the similar changes to PBS con-
trol. The supervised approach of PLS-DA was more focused on the ac-
tual class discriminating variation in the data compared to theunsupervised approach of PCA. A clear separation among the Tat-
induced group and the inaTat or control group was observed in the
PLS-DA score plot by the ﬁrst two components (Fig. 4B) (R2=0.89,
Q2=0.81). To validate the model, permutation tests with 100 itera-
tions were further performed. These permutation tests compared
the goodness of ﬁt of the original model with the goodness of ﬁt of
randomly permuted models. As shown in Fig. 4C, the validation plot
indicates that the original model is valid. The criteria for validity are
as follows: all the permuted R2 (cum) and Q2 (cum) values to the
left are lower than the original point to the right, and the blue regres-
sion line of the Q2 (cum) points has a negative intercept (Mahadevan
et al., 2008; Pasikanti et al., 2010).
Among the 214 metabolites detected, 98 metabolites were identi-
ﬁed from serum samples that differed statistically signiﬁcant between
the groups after correction for multiple comparisons (false discovery
rate Qb0.05). Variables that signiﬁcantly contributed to the clustering
and discrimination were identiﬁed according to a threshold of vari-
able importance in the projection (VIP) values (VIP >1), which
could be generated after PLS-DA processing. According to the VIP
value, the 30 variables were selected as the candidates of potential
biomarkers. Some of these variables were found to be from the
same metabolites. After merging the variables from the identical
Fig. 3. The typical total ion current chromatograms (TICs) of mouse sera from the control group (A), the inaTat group (B) and the Tat group (C).
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further restricted to features with an average intensity difference of
at least 1.5-fold (high or low) between inaTat- and Tat-induced sam-
ples. Following the criterion above, 16 signiﬁcantly differential vari-
ables were found, which were considered as potential biomarkers.
The results are listed in Table 1.
Discussion
The complex pathogenesis of HIV-1 Tat is still a challenging ﬁeld
and an effective in vivo model is necessary. To date, several Tat-
transgenic mice models have been successfully created to study
HIV-1 Tat-induced pathology (Giunta et al., 2009; Kim et al., 2003;
Prakash et al., 1997). Recently, Atrayee Banerjee et al. reported an
ICR mouse model injected intravenously with bioactive Tat protein
was used to study oxidative stress-induced damage in the brain and
potential role of antioxidant (Banerjee et al., 2010). In this study,
the similar ICR mouse model combined with GC/MS-based metabolo-
mic proﬁling approach was applied to investigate whether this sys-
tem could identify signatures associated with pathogenesis of the
Tat protein in Tat-treated mice serum. The GC/MS-based metabolic
proﬁling platform combined with multivariate statistical methods
(PCA and PLS-DA) has enabled us to highlight the organism's distinctresponse to Tat, and 16 metabolites were identiﬁed with statistically
signiﬁcant changes in Tat-induced mice, which are discussed as
follows.
Tryptophan was signiﬁcantly decreased in the serum of Tat-
induced mice. As essential amino acid, tryptophan uptake in the
diet may lead to the same result. We treated the mice for 5 days
with Tat protein, and observed that this treatment did not change
the animal diet behavior and cause weight loss. Therefore, it can
be presumed that the decrease of tryptophan in this study has
been probably attributed to increased tryptophan metabolism. Con-
sistent with our result, signiﬁcantly decreased blood levels of the es-
sential amino acid tryptophan in infected individuals were noted
fairly early on in the HIV epidemic (Larsson et al., 1989; Werner et
al., 1988). Conﬁrming those early reports, a 2003 survey of the
data from 16 published studies suggested that, despite adequate di-
etary intake, the average tryptophan blood level in HIV infected indi-
viduals is almost 30% below that of normal uninfected individuals
(Murray, 2003). The reduction of tryptophan could be due to two
factors. On the one hand, tryptophan can enter the brain where
it is degraded by the kynurenine pathway (Ruddick et al., 2006).
On the other hand, tryptophan may also be degraded in various
cells as Tat was found to up-regulate indoleamine-2,3-dioxygenase
(IDO), the rate-limiting enzyme of tryptophan metabolism, and
Fig. 4. (A) PCA score map derived from GC/MS spectra concerning control (■), inaTat
(▲) and Tat (♦) samples. (B) PLS-DA score map derived from GC/MS spectra concern-
ing control (■), inaTat (▲) and Tat (♦) samples. (C) Validation plot obtained from 100
permutation tests.
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(Samikkannu et al., 2010). This Tat-induced abnormal tryptophan
metabolism could be associated with its pathogenesis, which will
be further evaluated.
Lactate, a potential source of endogenous molecular toxins, is the
end product of glycolysis. Jiang et al. reported that increased lactate
is a key biomarker related to lipodystrophy (Jiang et al., 2008),
which often occurs in HIV-infected patients (Sekhar et al., 2002).
Lipodystrophy has not only been strongly associated with antiretrovi-
ral treatments, but it may be associated with the viral infection itself
(Slama et al., 2009). Recent studies indicate that some viral proteins
may impede adipocyte differentiation by decreasing peroxisome
proliferator-activated receptor-gamma (PPARγ) expression and con-
tribute to lipodystrophy (Shrivastav et al., 2008). Higher levels of lac-
tate were observed in the Tat-induced mice compared to inaTat and
control group in our study and we infer that the increased lactatelevel induced by the HIV-1 Tat protein may also contribute to HIV-
associated lipodystrophy.
Palmitinic acid and stearic acid were present in decreased levels in
the Tat-induced group, which suggested that Tat protein may inhibit
fatty acids synthesis or enhance β-oxidation of fatty acids. Arachido-
nic acid, a polyunsatured fatty acid, serving as a biologically active
signaling molecule as well as an important component of membrane
lipid, exerts many biological functions including modulation of the
activities of protein kinases and ion channels (Khan et al., 1995).
Jiang et al. provided evidence that HIV Tat promoted arachidonic
acid metabolism which contributed to HIV-1 Tat-mediated transacti-
vation, and drugs that anti-arachidonic acid properties may be re-
sponsible for their HIV-Tat inhibitory capability (Jiang et al., 1996).
In this study, arachidonic acid was proved again to be decreased in
Tat-treated mice, which suggested a possible link of arachidonic
acid pathway to bioactivity of HIV-1 Tat protein.
The citrate cycle is central to aerobic metabolism, facilitating ade-
quate throughout of substrates derived from carbohydrates, fatty
acids or certain amino acids (Sabatine et al., 2005). As pivotal inter-
mediates of TCA cycle, the decreased levels of citrate, succinate and
malate in the Tat-induced group indicated that TCA cycle was inhib-
ited. This phenomenon may be attributed to the decreased activity
of citrate synthase in mitochondria, where TCA metabolism occurs
(Prasada Rao and Gardner, 1986). In addition, Tat was previously
reported to induce oxidative stress (Pocernich et al., 2005), and
under the circumstance, TCA cycle slows during cellular regulation
to reduce the natural production of ROS (Huang et al., 2008). Thus,
we infer that the decreased levels of citrate, succinate and malate
are due to the dysfunction of mitochondria, and the block of natural
energy production by Tat-induced oxidative stress. In addition, α-
amino acids are critical to life and have a variety of roles in metabo-
lism. They are not only the building blocks of proteins and coenzymes
but are also important energy metabolismmaterials and can be trans-
formed into some metabolism intermediates such as pyruvate, oxa-
loacetic acid, oxoglutarate, citric acid and fumarate, to participate in
the tricarboxylic acid (TCA) cycle. In the Tat-induced group, four
amino acids (L-alanine, proline, phenylalanine and tyrosine) were de-
creased in circulation. One possible speculation was that oxidative
stress caused by Tat protein lead to the metabolic remodeling of α-
amino acids to meet energy requirement.
GC/MS analysis showed signiﬁcantly decreased levels of gluta-
mine in the serum of the Tat-induced mice. Glutamine is the main
precursor of the excitatory neurotransmitter glutamate. This gluta-
mine/glutamate cycle is essential for glutamine homeostasis and neu-
rotransmitter glutamate generation and recycling (Schousboe, 2003).
Glutamate induced neurotoxicity has been implicated in HIV-
associated dementia (Silvers et al., 2007), and the toxic effects are
closely related to the HIV Tat protein, which is involved in glutama-
tergic effects (Holden et al., 1999; Perez et al., 2001). Decreased
serum glutamine may contribute to glutamate induced neurotoxicity
(Ramonet et al., 2004).
Uric acid, which is involved in purine metabolism, was signiﬁcant-
ly decreased in the Tat-induced mice. Purine metabolism had been
studied in peripheral blood lymphocytes (PBL) of normal subjects
and HIV-l infected patients (Carlucci et al., 1996; Tabucchi et al.,
1992, 1993). It was found that viral penetration affected purine nucle-
otide metabolism of total PBL. Nucleosides and nucleobases, which
are catabolic products, were signiﬁcantly lower. In this study, uric
acid as catabolic products of purine metabolism was also decreased
in the Tat-induced mice. While we failed to detect other metabolites
in purine metabolism pathway, we cannot clearly delineate this im-
pact on purine metabolism. In addition, uric acid is an important
non-enzymatic antioxidant. The decreased levels of serum uric acid
indicated a defect in the antioxidant defense, which played an impor-
tant role in oxidative stress in HIV-associated dementia (Pocernich et
al., 2005).
Table 1
Potential biomarkers in Tat-induced mice serum.
Peak no. Identity Retention time (min) P valuea Fold changeb Control group mean (S.D.)c inaTat group mean (S.D.)d Tat group mean (S.D.)e
1 Lactate 7.72 b0.0001 0.64 6.0295 (0.4657) 6.1706 (0.4742) 9.6169 (0.5214)
2 L-alanine 9.00 0.0006 1.50 0.4806 (0.0753) 0.4754 (0.0788) 0.3178 (0.0549)
3 Succinate 16.19 b0.0001 1.61 0.0041 (0.0007) 0.0040 (0.0005) 0.0025 (0.0003)
4 Malate 21.48 0.0031 1.59 0.0077 (0.0014) 0.0068 (0.0017) 0.0043 (0.0006)
5 Proline 22.47 0.0004 1.97 0.0418 (0.0077) 0.0361 (0.0069) 0.0184 (0.0039)
6 Glutamine 25.38 0.0002 1.83 0.0156 (0.0031) 0.0135 (0.0027) 0.0074 (0.0014)
7 Phenylalanine 25.55 0.0001 1.85 0.0406 (0.0076) 0.0352 (0.0029) 0.0190 (0.0032)
8 Citrate 30.56 0.0010 1.59 0.0264 (0.0046) 0.0266 (0.0048) 0.0167 (0.0039)
9 Tyrosine 33.71 0.0032 1.70 0.0048 (0.0009) 0.0042 (0.0009) 0.0025 (0.0010)
10 Palmitinic acid 36.55 b0.0001 1.53 0.5553 (0.0398) 0.5210 (0.1052) 0.3416 (0.0698)
11 Uric acid 37.66 b0.0001 5.59 0.0146 (0.0018) 0.0139 (0.0026) 0.0025 (0.0005)
12 Tryptophan 40.17 0.0002 1.51 0.0100 (0.0012) 0.0084 (0.0013) 0.0055 (0.0008)
13 Linoleic acid 40.25 b0.0001 1.61 0.1625 (0.0101) 0.1593 (0.0142) 0.0988 (0.0153)
14 Stearic acid 40.93 0.0003 1.55 0.1102 (0.0104) 0.1061 (0.0219) 0.0683 (0.0121)
15 Arachidonic acid 42.81 0.0002 1.61 0.0035 (0.0005) 0.0034 (0.0006) 0.0021 (0.0004)
16 α-Tocopherol 48.78 0.0005 1.51 0.0115 (0.0013) 0.0113 (0.0023) 0.0075 (0.0012)
a Tat group versus inaTat group.
b The fold change of relative amounts of the inaTat group compared to the Tat group.
c The ratio of peak area to the internal standard on the same chromatogram from the control group; the data were represented as the mean (S.D.).
d The ratio of peak area to the internal standard on the same chromatogram from the inaTat group.
e The ratio of peak area to the internal standard on the same chromatogram from the Tat group.
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which was consistent with the variation tendency of α-tocopherol
levels in the plasma samples of monkeys with SIVE (Pendyala et al.,
2010). α-Tocopherol is an important compound of vitamin E, which
is comprised of eight related tocopherols and tocotrienols, and main-
tains physiological cellular and tissue functions through the antioxi-
dant properties of these compounds. The decreased levels of α-
tocopherol may contribute to oxidation stress damage induced by
the HIV Tat protein (Pocernich et al., 2005).Fig. 5. The integrative view plot of the metabolite change induced by the Tat protein in the ci
values are the relative peak area ratios of the 16 metabolites to ribitol.Based on our ﬁndings, an integrative view plot of the metabolite
change induced by Tat protein in the circulation system is shown in
Fig. 5. In conclusion, this is the ﬁrst metabolomic study to determine
the biochemical alterations in the serum of HIV-1 Tat-induced mice
by using GC/MS. We identiﬁed 16 signiﬁcantly changed metabolites
involved in amino acid metabolism, glycolysis, TCA cycle and fatty
acid metabolism, which were helpful for revealing the complex path-
ogenic mechanism of HIV-1 Tat as a viral toxin and may shed new
light on future improvements of HIV-1 therapy.rculation system. Column value in histograms is expressed as mean±S.D., in which the
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Sample collection and preparation
All mice were sacriﬁced 6 days after the treatment, and sera were
collected into standard vials from the retro-orbital venous sinus.
Blood samples were allowed to clot at room temperature for
30 min, and then the serum was separated by centrifugation at
3000 ×g for 10 min at 4 °C and stored at −70 °C until the analysis.
Before the analysis, serum (100 μl) was transferred into a centri-
fuge tube and spiked with the internal standard (5 μl of 1 mg/ml of
ribitol), followed by adding 400 μl of methanol/acetonitrile/acetone
(1:1:1, v/v/v) (Bruce et al., 2009) into the tube. After vigorous shaking
for 1 min and incubation on ice for 10 min, the mixture was centri-
fuged at 14,000 ×g for 15 min at 4 °C to precipitate the protein. The
supernatant (200 μl) was transferred into a GC vial and dried with a
gentle nitrogen stream. The derivatization was performed using
methoxyamine pyridine (75 μl; 15 mg/ml) at 70 °C for 1 h, followed
by MSTFA (75 μl) with 1% TMCS as catalyst at room temperature for
1 h. n-Heptane (200 μl) was added to dilute the solution after the de-
rivatization, and the supernatant was used for GC/MS analysis.
GC/MS analysis
The derivatized samples for GC/MS were analyzed on a Thermo-
Finnigan Trace DSQ fasting scanning single-quadrupole MS (Thermo
Electron Corporation) operated at unit mass resolving power. A
0.5 μl of sample solution was injected with splitless mode to a TR-
5MS column (30 m×250 μm×0.25 μm) with helium as the carrier
gas at a ﬂow of 1 ml/min. The injector temperature was set at
260 °C. The temperature of the ion source was adjusted to 200 °C
and that of the quadrupole was set at 150 °C. GC/MS was operated
using electron impact ionization with a 60–600 amu scan range. The
initial temperature of the column was kept at 70 °C for 3 min. Then,
the temperature was ramped at 4 °C/min to 220 °C and then to
310 °C at a rate of 12 °C/min where it was held for 10 min. To reduce
systematic error associated with instrument drift, samples were run
in an order that alternated between the Tat-induced group and the
control group. Each sample was run in duplicate, and after data inte-
gration, duplicate runs were averaged.
We ﬁrst searched the NIST database installed in the Thermo-
Finnigan Trace DSQ GC/MS system for the identiﬁcation of the metab-
olites based on the GC/MS data. Candidate compounds showing
higher similarities (>75%) were selected. Lastly, the exact identities
of the metabolites of interest were veriﬁed by commercial standards.
System stability
To evaluate the applicability of the GC/MS method, an equal vol-
ume of each sample was pooled together to construct an artiﬁcial
sample. This sample was processed as a real sample, and then it was
randomly inserted in the real sample queue to be analyzed six times
accordingly. The system stability was expressed as the relative stan-
dard deviation (RSD) of the relative peak areas, i.e., the ratios of the
peak areas of the metabolites to that of the internal standard. Eight
common extracted ion chromatograms (EICs) shared by these injec-
tions were selected based on their relatively high abundance levels
and wide retention time distribution range in the chromatogram.
Data analysis
Data in an instrument-speciﬁc format were converted to CDF for-
mat ﬁles. The program XCMS was used for nonlinear alignment of the
data in the time domain and automatic integration and extraction of
the peak intensities. XCMS parameters were default settings except
for the following: fwhm=4, bw=5 and snthersh=5. The outputdata were imported into MATLAB 7.0 software (The MathWorks,
Inc., USA), where data were normalized using the summation of re-
sponse of all metabolites in one sample and then calculated the ratios
of the intensities of mass ions to that of the internal standard frag-
ment ion (m/z 216.9, it is the most abundance fragment ion for the
silylation derivative of ribitol).
It should be noted that GC/MS data inherently contain apparent
variability and complexity, such as multiple fragment ions from a sin-
gle compound. Directly concatenating the matrices of processed-MS
data is suboptimal as this may result in a matrix with an unfavorable
samples-to-variables ratio. It is necessary to use a properly reduced
matrix to conduct multivariate statistical analysis. A simple strategy
was untargeted ﬁltration of ion peaks using our in-house scripts in
the MATLAB 7.0, where the most abundant fragment ion with the
same retention time (the time bin is 0.01 min) remained and the
other ions were excluded.
The processed data list was exported and processed by the princi-
pal component analysis (PCA) and partial least-squares discriminant
analysis (PLS-DA) in SIMCA-P software (Version 11, Umetrics). It
should be noted that data were log transformed for multivariate anal-
ysis to eliminate the unit error. The signiﬁcance was expressed by
using one-way ANOVA analysis of the SPSS 13.0 for Windows (SPSS
Inc., Chicago, IL, USA). P-values less than 0.05 were considered signif-
icant. Signiﬁcant peak changes between samples were conﬁrmed by
manual quantiﬁcation by calculating the area under the peak from
raw chromatograms. To account for multiple comparisons, false dis-
covery rate was estimated as the maximum Q value (Storey, 2002)
in the set of signiﬁcant differences for the metabolomic data set.
False discovery rates were computed using the R package Q value.
The signiﬁcance of the group differences was evaluated by the P
value for the ﬁxed-effect parameter estimate of group differences.
Materials and methods
The schematic ﬂowchart of the metabolic proﬁling strategy used
in this study is illustrated in Fig. 1.
Reagents
Methoxylamine hydrochloride, N-methyl-N-(trimethylsilyl)-tri-
ﬂuoracetamide (MSTFA), pyridine, trimethyl-chlorosilane (TMCS),
n-heptane, acetone, and citrate were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Methanol and acetonitrile are chromatography
pure (Merck, Germany). The following compounds were obtained
from Shanghai Jingchun Reagent Co.: ribitol, lactate, L-alanine, sodi-
um succinate, malic acid, L-proline, L-glutamine, phenylalanine, tyro-
sine, palmitinic acid, stearic acid, linoleic acid and arachidonic acid.
Preparation of recombinant Tat protein
The DNA encoding for Tat protein (1–86 aa) from the BH-10 clone
of the IIIB strain of HIV-1 (clade B) was ampliﬁed by overlapping PCR
and cloned into the NdeI and XhoI site of the bacterial expression vec-
tor pET21b (Novagen) under the control of the T7 promoter. We
added a His-tag of 6 amino acid residues to the C-terminus of Tat to
facilitate puriﬁcation via Ni–NTA chromatography, and we expressed
the protein in E. coli. The Tat protein was then puriﬁed as previously
described (Siddappa et al., 2006). Brieﬂy, individual bacterial colonies
(E. coli BL21 (DE3)) were grown in 1 l cultures in LB medium supple-
mented with 100 μg/ml ampicillin. Protein production was induced
by adding IPTG at ﬁnal concentration of 1 mM to the cultures when
they reached an OD of 0.4, and we incubated the cultures for an addi-
tional 3 h at 37 °C. The protein was identiﬁed in its soluble form. Cells
were harvested by high-speed centrifugation and resuspended in
20 ml of lysis buffer. The bacteria were lysed by sonication and then
centrifuged at 14,000 ×g for 30 min at 4 °C to remove cell debris.
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chromatography (a Ni–NTA column (QIAGEN)), and then further pu-
riﬁed by SP Sepharose fast ﬂow ion-exchange chromatography
(Amersham Biosciences) following the manufacturer's instructions.
The lyophilized Tat protein was resuspended in degassed PBS just be-
fore use. Tat protein was heat-inactivated by incubation at 85 °C for
30 min as previously described (Avraham et al., 2004). The heat-
inactivated Tat protein (inaTat) has been extensively used as a nega-
tive control for bioactive Tat (Avraham et al., 2004; Chi et al., 2011;
Perry et al., 2010) and was used as a control for the Tat-induced bio-
chemical changes in this study.
Endotoxin level of puriﬁed recombinant Tat protein was deter-
mined using the Limulus amebocyte lysate test (BioWhittaker, Inc.).
Western blot analysis of the recombinant Tat protein
The recombinant Tat protein was boiled for 5 min in gel loading
buffer, resolved on a 15% SDS-PAGE gel, and then transferred to a
polyvinylidene diﬂuoride (PVDF) membrane (Pharmacia). The mem-
brane was blocked with 3% BSA and probed with an anti-Tat mono-
clonal antibody (NIH AIDS Reagent Repository), diluted at 1:1000 in
PBS, at room temperature for 2 h. Membranes were washed and incu-
bated with a secondary antibody conjugated to horseradish peroxi-
dase (Sigma, St. Louis, Mo). The blot was developed by incubating
the membrane in the substrate solution containing 3 μl/ml H2O2 and
0.5 mg/ml 3,3′-diaminobenzidine tetrahydrochloride (Sigma, St.
Louis, Mo) in PBS.
Identiﬁcation of bioactivity of the recombinant Tat protein
Human embryonic kidney (HEK) 293T cells (purchased from the
Cell Bank of Shanghai Institutes for Biological Sciences, Chinese Acad-
emy of Sciences, Shanghai, China) seeded in 96-well plates were tran-
siently transfected with 0.5 μg of a plasmid vector encoding green
ﬂuorescent protein (GFP) and secreted alkaline phosphatase (SEAP)
under the control of the subtype-B LTR (B-LTR) (pLTR-GFP, provided
by Dr. Udaykumar Ranga) using a commercial lipid formulation fol-
lowing the manufacturer's directions (Invitrogen). Twenty-four
hours after the transfection, the cells were incubated with bioactive
Tat protein or inaTat at a ﬁnal concentration of 5 μg/ml in complete
medium. Twenty-four hours following the protein transfection, ex-
pression of GFP was measured using UV-ﬂuorescence microscopy. Ex-
pression of alkaline phosphatase secreted into the medium was
estimated at 24 h using lumino-meter (Toyobo). Cells transfected
with the pLTR-GFP plasmid were included as a negative control.
Animal experiments
Twenty-four male ICR mice, 8 weeks of age and weighing approx-
imately 30 g, were provided by the Experimental Animal Center of
the Second Military Medical University (Shanghai, China). The colony
room was maintained at proper temperature and humidity and was
on a 12 h light/dark cycle. The animals had unlimited access to rodent
chow and water, and they were used after 1 week of acclimatization.
Twenty-four male ICR mice were randomly divided into three groups
(n=8): Tat group (100 ng in PBS, i.v.), inaTat group (100 ng in PBS,
i.v.) and control group (PBS, i.v.). The mice were administered Tat,
inaTat, or PBS for 5 consecutive days as previously described
(Banerjee et al., 2010).
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